- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02438449
Cost-Effectiveness of Abdominal-based Autogenous Tissue vs Tissue Expander-Implant Reconstruction - A Feasibility Study
February 24, 2021 updated by: Achilleas Thoma, McMaster University
A Cost-Effectiveness Analysis Comparing Abdominal-based Autogenous Tissue (AAT) and Tissue Expander- Implant (TE/I) Reconstruction of the Breast After Mastectomy- A Feasibility Study
It is estimated that about 25% and 40% of health care expenditures in Canada and USA respectively are wasted because of inefficiencies and not practicing evidence-based medicine.
As health care resources are scarce it behooves all of us to use these in a cost-effective manner.
The term "cost-effective" is used in the health care literature often but erroneously.
Investigators compare a "novel' intervention to a "prevailing" one and if the novel intervention is less costly it is labeled "cost-effective".
In a methodologically correct cost-effectiveness study however, investigators need to integrate both the effectiveness and costs of the competing interventions and calculate an incremental cost-effective ratio.
If this ratio falls within acceptability thresholds, the novel intervention is labeled cost-effective.
There are many techniques of breast reconstruction.
The two most common approaches are the Autologous Abdominal Tissue (AAT) and the Tissue Expansion / Implant reconstructions.
In this study these two most common breast reconstruction approaches after mastectomy due to cancer performed in the Hamilton/Niagara/Haldimand/Brant and Waterloo/Wellington LHINs will be investigated with a cost-effectiveness analysis coupled with a methodologically robust observational study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
As a result of the recent advances in the treatment of breast cancer carried out by dedicated researchers and made possible through breast cancer research, its mortality has been gradually declining.
Naturally, the quality of survivorship has taken an important role in the last 3 decades.
Unfortunately, for most women with breast cancer, their concerns about survival are followed closely with concerns about body image, sexuality, self-esteem and social life.
Mastectomy, a mainstay in the treatment of breast cancer, is the primary cause of these latter concerns.
The investigators are therefore charged with looking at the disease and the respective treatment of breast cancer holistically.
Providing a comprehensive management of breast cancer today requires attention to both oncologic principles and to the patient's quality of life.
A large part of the patient's quality of life comes from improved reconstructive and aesthetic outcomes following mastectomy.
In short, breast reconstruction after mastectomy for cancer aims to improve body image and quality of life by reducing the negative psychological impact of the deformity.
Multiple techniques exist to accomplish this goal.
They include breast implants, autologous tissues, or occasionally, a combination thereof.
Although the ultimate goal is to recreate an aesthetically pleasing breast that attempts to match the missing one, the decision to use a particular technique is multi-factorial.
It may be influenced by the surgeon's skills, the patient's preferences, inherent contraindications with a patient, or the resources available in a particular setting.
Breast reconstructions can be costly to patients (indirect costs), third party payers and society, especially as new technologies are introduced in clinical practice.
In the last 2 decades third party payers and governments in different jurisdictions have been advocating for production of evidence that shows "value for money" germane to these different procedures.Presently, the two most common approaches to breast reconstruction are the AAT method and the TE/I method.
These two approaches to breast reconstruction have yet to be submitted to an economic evaluation using state-of-the-art cost-effectiveness analysis.
Study Type
Observational
Enrollment (Actual)
61
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare / McMaster University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
The study population will include patients undergoing breast reconstruction after mastectomy on one or both breasts being seen by one of the participating plastic surgeons.
If patients qualify for the trial according to the inclusion and exclusion criteria, they will be invited to participate in the study and will be required to provide written informed consent.
Description
Inclusion Criteria:
- Patients 18 years of age or older.
- Patients undergoing breast reconstruction (immediate or delayed) after mastectomy procedure on one or both breasts.
- Eligible for two step tissue expander and implant based procedure, or one of the following autogenous abdomen tissue-based procedures (pedicled TRAM flap, Free TRAM, ms TRAM flap, DIEP flap, SIEA flap, Rubens flap).
Exclusion Criteria:
- Patients who have had previous breast reconstruction surgery.
- Patients undergoing other procedures during reconstruction surgery, other than the mastectomy itself in the case of immediate or delayed reconstruction.
- Patients unable to complete the questionnaires due to language barriers.
- Geographic inaccessibility or inability to adhere to study protocol requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Abdominal-based Autogenous Tissue (AAT)
The AAT-based breast reconstruction surgery will include any of the following techniques: pedicled transverse rectus abdominis myocutaneous (TRAM) flap, Free TRAM, muscle-sparting TRAM flap, deep inferior epigastric perforator (DIEP) flap, superficial inferior epigastric artery (SIEA) flap, and Rubens flap.
|
AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
|
|
Tissue Expander-Implants (TE/I)
The TE/I approach will include two-stage breast reconstruction surgery.
In the initial stage, immediately after mastectomy and with or without sentinel node biopsy, an expander will be placed in the subpectoral plane and the defect closed.
Two weeks after the surgery, the expansion of the TE will commence until the desired volume of the respective expander is achieved.
The second stage will include removal of the TE and the placement of a permanent implant which may be either saline or gel.
The delayed method will be similar to the immediate reconstruction with the exception of the incision, which will be relatively smaller as the mastectomy was performed previously with breast cavity being fully closed.
|
AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Health-related Quality of Life (utilities and disease-specific)
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Healthcare resource utilization including out-of-pocket expenses by patients
Time Frame: 1 year
|
Identify and tabulate the costs for the two procedures under the purview of the patient, Ministry of Health and society.
Costs will be further classified into two categories: surgery-related costs and costs incurred by the patient.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (Actual)
September 1, 2018
Study Completion (Actual)
April 1, 2020
Study Registration Dates
First Submitted
April 23, 2015
First Submitted That Met QC Criteria
May 5, 2015
First Posted (Estimate)
May 8, 2015
Study Record Updates
Last Update Posted (Actual)
February 25, 2021
Last Update Submitted That Met QC Criteria
February 24, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MSA-2015-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Breast Reconstruction Surgery
-
The Netherlands Cancer InstituteMaastricht University Medical Center; Erasmus Medical Center; Ziekenhuisgroep... and other collaboratorsEnrolling by invitationAutoimmune Diseases | Breast Cancer | Breast Implant; ComplicationsNetherlands
-
Assiut UniversityUnknown
-
Fudan UniversityThe First Affiliated Hospital with Nanjing Medical University; First People... and other collaboratorsRecruitingBreast Cancer | Breast Reconstruction | Patient Reported Outcome Measures | Oncoplastic Breast-conserving SurgeryChina
-
Henan Cancer HospitalRecruiting
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingQuality of Life | Breast Cancer | SurgeryChina
-
Du ZhengguiShanxi Province Cancer Hospital; Guangzhou First People's Hospital; The First... and other collaboratorsNot yet recruiting
-
Centre Georges Francois LeclercActive, not recruiting
-
Vastra Gotaland RegionRecruitingBreast Cancer | Weight Loss | Breast Reconstruction | Surgical Complication | Bariatric Surgery | Breast Implant Infection | Breast Implant | MastopexySweden
-
M.D. Anderson Cancer CenterRecruiting
-
Case Comprehensive Cancer CenterWithdrawnBreast Cancer | Malignant Neoplasm of BreastUnited States